S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Myriad Genetics (MYGN) Earnings Date, Estimates & Call Transcripts

$18.64
-0.28 (-1.48%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 1Estimated
Actual EPS
(Feb. 27)
$0.04 Beat By $0.03
Consensus EPS
(Feb. 27)
$0.01
Skip Charts & View Estimated and Actual Earnings Data

MYGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MYGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Myriad Genetics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($0.15)($0.13)($0.14) 
Q2 20242($0.07)($0.06)($0.07) 
Q3 20242($0.07)($0.06)($0.07) 
Q4 20242($0.04)($0.02)($0.03) 
FY 20248($0.33)($0.27) ($0.30)

MYGN Earnings Date and Information

Myriad Genetics last released its quarterly earnings results on February 27th, 2024. The reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The firm had revenue of $196.60 million for the quarter, compared to analysts' expectations of $194.80 million. Its revenue for the quarter was up 10.6% compared to the same quarter last year. Myriad Genetics has generated ($3.20) earnings per share over the last year (($3.20) diluted earnings per share). Earnings for Myriad Genetics are expected to grow in the coming year, from ($0.36) to ($0.08) per share. Myriad Genetics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off prior year's report dates.

Myriad Genetics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/1/2024
Estimated)
------- 
2/27/2024Q4 2023$0.01$0.04+$0.03$0.22$194.80 million$196.60 million      
11/6/2023Q3 2023($0.08)($0.03)+$0.05$0.41$179.23 million$191.90 million      
8/3/2023Q2 2023($0.08)($0.08)-$1.00$187.16 million$183.50 million    
5/3/2023Q1 2023($0.19)($0.21)($0.02)$0.11$171.56 million$181.20 million    
2/28/2023Q4 2022($0.27)($0.20)+$0.07$0.12$169.16 million$177.80 million
11/1/2022Q3 2022($0.15)($0.27)($0.12)($0.11)$172.12 million$156.40 million
8/4/2022Q2 2022($0.09)($0.06)+$0.03$0.06$170.05 million$179.30 million    
5/5/2022Q1 2022($0.15)($0.14)+$0.01($0.02)$156.09 million$164.90 million      
2/24/2022Q4 2021($0.15)($0.11)+$0.04($0.12)$162.21 million$160.80 million    
11/2/2021Q3 2021($0.02)($0.02)-($0.54)$164.35 million$167.30 million    
8/3/2021Q2 2021($0.09)$0.12+$0.21$0.12$163.09 million$189.40 million  
5/2/2021Q1 2021($0.15)($0.06)+$0.09$0.20$155.36 million$173.10 million  

Myriad Genetics Earnings - Frequently Asked Questions

When is Myriad Genetics's earnings date?

Myriad Genetics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off last year's report dates. Learn more on MYGN's earnings history.

Did Myriad Genetics beat their earnings estimates last quarter?

In the previous quarter, Myriad Genetics (NASDAQ:MYGN) reported $0.04 earnings per share (EPS) to beat the analysts' consensus estimate of $0.01 by $0.03. Learn more on analysts' earnings estimate vs. MYGN's actual earnings.

How can I listen to Myriad Genetics's earnings conference call?

The conference call for Myriad Genetics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Myriad Genetics's conference call transcript?

The conference call transcript for Myriad Genetics's latest earnings report can be read online. Read Transcript

How can I view Myriad Genetics's earnings report?

Myriad Genetics's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Myriad Genetics generate each year?

Myriad Genetics (NASDAQ:MYGN) has a recorded annual revenue of $753.20 million.

How much profit does Myriad Genetics generate each year?

Myriad Genetics (NASDAQ:MYGN) has a recorded net income of -$263.30 million. MYGN has generated -$3.20 earnings per share over the last four quarters.

What is Myriad Genetics's EPS forecast for next year?

Myriad Genetics's earnings are expected to grow from ($0.36) per share to ($0.08) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:MYGN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners